No Data
Express News | Brii Biosciences - Does Not Expect Material Impacts on Its Business Operation and Financial Performance Due to VBI's Insolvency
Express News | Brii Biosciences Ltd - on July 30, VBI Vaccines Initiated Restructuring Proceedings
Robert Taylor Nelsen resigned as non-executive director of Tengshengbo Medicine B (02137).
Tengshengbo Medicine-B (02137) released an announcement, Mr. Robert Taylor Nelsen...
Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference
Express News | Brii Bio Presents New Data From Its Ongoing Phase 2 Chronic Hepatitis B Trials at Easl™ Congress 2024
Tengshengbo Medicine-B (02137.HK) released new data from two phase 2 studies at the European Liver Research Association Congress in 2024.
On June 7th, National Business Daily announced that Tengshengbo Medicine-B (02137.HK) released new data from two Phase 2 studies at the European Liver Association Congress in 2024. These data evaluated the efficacy of BRII-179 and BRII-835 (elebsiran) combined therapy or BRII-179 as an adjuvant therapy combined with pegylated interferon α (PEG-IFNα) in the treatment of chronic hepatitis B virus (HBV) infection. Oral report data from a Phase 2 clinical trial showed that in some chronic HBV-infected subjects, the therapeutic vaccine, BRII
No Data
